文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

右美托咪定对脓毒症急性肾损伤大鼠肾组织紧密连接蛋白ZO-1表达的影响

[Effect of dexmedetomidine on expression of tight junction protein ZO-1 in kidney tissue of rats with acute kidney injury induced by sepsis].
PubMed 文献 · Zhonghua Wei Zhong Bing Ji Jiu Yi Xue · 2020-01-01
一句话结论大鼠脓毒症模型中,右美托咪定预处理可上调肾组织ZO-1表达并减轻肾损伤病理评分,属动物实验证据。

该研究将60只健康雄性SD大鼠随机分为假手术组、右美托咪定+假手术组、盲肠结扎穿刺(CLP)组和右美托咪定+CLP组,每组15只,术后6、12、24小时各取5只。右美托咪定组于造模前1小时经尾静脉以5 μg×kg-1×h-1泵入右美托咪定,对照组泵入等量生理盐水。结果显示CLP组各时间点肾损伤病理评分显著高于假手术组、ZO-1阳性表达面积显著降低(均P<0.01);右美托咪定+CLP组较CLP组病理评分显著降低、ZO-1阳性表达面积显著升高(均P<0.01)。结论提示右美托咪定可能通过上调ZO-1减轻脓毒症诱导的急性肾损伤。

要点

  • 动物实验:CLP造模前1小时经尾静脉泵入右美托咪定5 μg×kg-1×h-1,可降低脓毒症大鼠6、12、24小时肾损伤病理评分(均P<0.01)。
  • CLP组肾组织ZO-1阳性面积百分比各时间点显著低于假手术组(6小时3.17±0.74% vs. 10.83±0.83%,P<0.01)。
  • 右美托咪定+CLP组ZO-1阳性面积百分比较CLP组显著升高(6小时8.58±0.86% vs. 3.17±0.74%,P<0.01)。
  • 右美托咪定+假手术组与假手术组肾损伤病理评分及ZO-1表达无显著差异。
  • 结论为「可能」通过上调ZO-1减轻脓毒症相关AKI,属机制假说,尚未在临床验证。

适用人群与场景

  • 健康雄性Sprague-Dawley大鼠,脓毒症模型采用改良盲肠结扎穿刺(CLP)法建立。
  • 假手术组与右美托咪定+假手术组仅行开腹关腹,不造脓毒症模型。
  • 原文未提及临床患者人群、排除标准或ICU/急诊适用人群。

诊断标准与关键阈值

  • 脓毒症模型:改良CLP法(原文未给出具体结扎长度、穿刺针型号等参数)。
  • 肾损伤评估:HE染色光镜下观察病理改变并计算肾损伤病理评分(原文未给出评分量表名称与界值)。
  • ZO-1表达:免疫组化检测肾组织ZO-1阳性表达水平,以阳性面积百分比表示。

处置流程与药物剂量

  • 第一步:造模前1小时给予预处理。
  • 第二步:右美托咪定+假手术组与右美托咪定+CLP组经尾静脉以5 μg×kg-1×h-1速率泵入右美托咪定。
  • 第三步:假手术组与CLP组经尾静脉泵入等量生理盐水。
  • 第四步:术后6、12、24小时各处死大鼠取肾组织行HE染色与免疫组化。
  • 原文未提及临床给药剂量、途径、频次或目标值,上述为大鼠实验方案,不能直接外推为临床推荐。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:动物实验(大鼠),60只健康雄性SD大鼠,单中心,随机数字表分为4组,每组15只,各组分6、12、24小时3个亚组,每亚组5只。
  • 与假手术组相比,CLP组各时间点肾损伤病理评分显著升高(6小时1.98±0.37 vs. 0.36±0.25;12小时2.62±0.34 vs. 0.39±0.18;24小时3.52±0.34 vs. 0.42±0.20,均P<0.01)。
  • 与假手术组相比,CLP组肾组织ZO-1阳性面积百分比显著降低(6小时3.17±0.74% vs. 10.83±0.83%;12小时2.56±0.76% vs. 9.02±0.88%;24小时1.75±0.66% vs. 8.25±0.94%,均P<0.01)。
  • 与CLP组相比,右美托咪定+CLP组各时间点肾损伤病理评分显著降低(6小时0.66±0.27 vs. 1.98±0.37;12小时1.34±0.26 vs. 2.62±0.34;24小时2.08±0.38 vs. 3.52±0.34,均P<0.01)。
  • 与CLP组相比,右美托咪定+CLP组肾组织ZO-1阳性面积百分比显著升高(6小时8.58±0.86% vs. 3.17±0.74%;12小时7.44±1.05% vs. 2.56±0.76%;24小时6.60±0.87% vs. 1.75±0.66%,均P<0.01)。
  • 右美托咪定+假手术组与假手术组肾损伤病理评分及ZO-1阳性表达无显著差异。

证据类型、等级与局限

  • 证据类型:动物实验(大鼠CLP模型),非RCT、非临床研究。
  • 局限:动物实验、样本量小(每组15只、每亚组5只)、单中心、预处理给药(造模前1小时)而非治疗性给药,结论为「可能」机制推断,需临床研究验证。

对床旁实践的改变

  • 该文为大鼠机制研究,不能直接改变急诊/ICU对脓毒症AKI的临床用药决策。
  • 原文提示右美托咪定可能通过上调肾组织ZO-1减轻脓毒症相关肾损伤,可作为机制假说参考,不构成临床推荐。
  • 原文给药为造模前1小时预处理、尾静脉5 μg×kg-1×h-1泵入,与临床镇静镇痛实际用药时机和方案不同,不可直接套用。
  • 原文未提及临床适用人群、不适用人群或常见陷阱。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

OBJECTIVE: To observe the effect of dexmedetomidine (DEX) on the expression of tight junction protein ZO-1 in kidney tissues of rats with acute kidney injury (AKI) induced by sepsis.

METHODS: Sixty healthy male Sprague-Dawley rats were selected and divided into four groups: sham operation group (Sham group), DEX + Sham group, cecal ligation and puncture (CLP) group and DEX + CLP group according to a random number table, with 15 rats in each group. Each group was then divided into 3 subgroups at 6, 12, and 24 hours after the operation, with 5 rats in each subgroup. Modified CLP was used to establish a sepsis model. In Sham group and DEX + Sham group, only laparotomy and abdominal closure were performed. Each group was given pretreatment 1 hour before modeling. DEX + Sham group and DEX + CLP group were pumped into DEX at a rate of 5 μg×kg-1×h-1 through the caudal vein; Sham group and CLP group were pumped with the equal amount of normal saline through the caudal vein. Rats in each group were sacrificed at 6, 12, and 24 hours after operation to obtain kidney tissue. After hematoxylin-eosin (HE) staining, the pathological changes were observed under a light microscope, and the pathological score of renal injury was calculated. The positive expression level of ZO-1 in kidney tissue was detected by immunohistochemistry.

RESULTS: The pathological changes of rat kidney tissue could be seen at 6 hours after CLP. With the prolongation of postoperative time, the degree of renal injury showed a tendency to aggravate, with 24 hours being more significant. Semi-quantitative analysis showed that compared with the Sham group, the CLP group had significantly higher renal injury pathology scores at each time point (1.98±0.37 vs. 0.36±0.25 at 6 hours, 2.62±0.34 vs. 0.39±0.18 at 12 hours, 3.52±0.34 vs. 0.42±0.20 at 24 hours,all P < 0.01); the positive expression level of ZO-1 in kidney tissue was significantly reduced [percentage of positive area: (3.17±0.74)% vs. (10.83±0.83)% at 6 hours, (2.56±0.76)% vs. (9.02±0.88)% at 12 hours, (1.75±0.66)% vs. (8.25±0.94)% at 24 hours, all P < 0.01]. Compared with the CLP group, the pathological score of renal injury in the DEX + CLP group was significantly reduced at each time point (0.66±0.27 vs. 1.98±0.37 at 6 hours, 1.34±0.26 vs. 2.62±0.34 at 12 hours, 2.08±0.38 vs. 3.52±0.34 at 24 hours, all P < 0.01); the positive expression level of ZO-1 in kidney tissue was significantly increased [percentage of positive area: (8.58±0.86)% vs. (3.17±0.74)% at 6 hours, (7.44±1.05)% vs. (2.56±0.76)% at 12 hours, (6.60±0.87)% vs. (1.75±0.66)% at 24 hours, all P < 0.01]. There was no significant difference in renal injury pathology score and ZO-1 positive expression between the DEX+Sham group and the Sham group.

CONCLUSIONS: DEX may reduce sepsis-induced AKI in rats by up-regulating the expression of tight junction protein ZO-1 in kidney tissue.

来源:Zhonghua Wei Zhong Bing Ji Jiu Yi Xue,查看原文。版权归原作者所有。

参考来源

  1. Yang H, Zhou W, Ma S, et al. [Effect of dexmedetomidine on expression of tight junction protein ZO-1 in kidney tissue of rats with acute kidney injury induced by sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020. PMID: 33541499. doi:10.3760/cma.j.cn121430-20200402-00251

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。